Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

Alice Tison 1 Gilles Quéré 1 Laurent Misery 1 Elisa Funck-Brentano 2 François Danlos 3 Emilie Routier 4 Caroline Robert 4 Yohann Loriot 5 Olivier Lambotte 6 Bertille Bonniaud 7 Camille Scalbert 8 Sarah Maanaoui 8 Thierry Lesimple 9 Stéphanie Martinez 10 Marie Marcq 11 Christos Chouaid 12 Catherine Dubos 13 Florence Brunet-Possenti 14 Chloé Stavris 15 Laurent Chiche 15 Nathalie Beneton 16 Sandrine Mansard 17 Florian Guisier 18 Hélène Doubre 19 François Skowron 20 François Aubin 21 Ouidad Zehou 22 Christophe Roge 23 Mickaël Lambert 23 Anne Pham-Ledard 24 Marie Beylot-Barry 24 Rémi Veillon 24 Nora Kramkimel 25 Damien Giacchero 26 Julie De Quatrebarbes 27 Catherine Michel 28 Jean-Bernard Auliac 29 Gilles Gonzales 30 Chantal Decroisette 27 Gwenaelle Le Garff 31 Ioana Carpiuc 32 Hervé Vallerand 33 Emmanuel Nowak 1 Divi Cornec 34, 35 Marie Kostine 24
1 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
2 AP - HP - Hôpital Ambroise Paré , Assistance Publique - Hôpitaux de Paris
3 IGR - Institut Gustave Roussy
4 Oncologie dermatologique
Département de médecine oncologique [Gustave Roussy]
5 Oncologie génito-urinaire
Département de médecine oncologique [Gustave Roussy]
6 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
7 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
8 CHRU Lille - Centre Hospitalier Régional Universitaire [Lille]
9 CRLCC - Centre Eugène Marquis
10 Hopital d'Aix en Provence
11 CHD Vendee (La Roche Sur Yon)
12 CHI Créteil
13 CRLC François Baclesse - Centre Régional de Lutte contre le Cancer François Baclesse
14 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
15 Hôpital Européen [Fondation Ambroise Paré - Marseille]
16 CHU Le MAns
17 CHU Clermont-Ferrand
18 CHU Rouen
19 Hôpital Foch [Suresnes]
20 CH DE VALENCE - Centre Hospitalier de Valence
21 CHU Besançon
22 CHU Henri Mondor
23 CH Morlaix
24 CHU Bordeaux [Bordeaux]
25 CHU Cochin [AP-HP]
26 Centre Antoine Lacassagne de Nice
27 Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
28 CH E.Muller Mulhouse - Centre Hospitalier Emile Muller [Mulhouse]
29 CH, Mantes-La-Jolie
30 Centre hospitalier Les Chanaux [Mâcon]
31 Hôpital de St Brieuc
32 Clinique des Cèdres
33 Service de Médecine Respiratoire [CHU Reims]
34 LBAI - Lymphocyte B et Auto-immunité
35 CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie
Abstract : Immune Checkpoint Inhibitors (ICI) for cancer therapy induce frequent Immune Related Adverse Effects (IRAE). Therefore, most patients with Preexisting Autoimmune Diseases (PAD) have been excluded from clinical trials. This study aims to evaluate the safety and efficacy of ICI in patients with PAD and cancer.
Keywords : immune checkpoint inhibitors autoimmune disease immune-related adverse events cancer immunotherapy
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02267195
Contributor : Geneviève Michel <>
Submitted on : Monday, August 19, 2019 - 10:22:34 AM
Last modification on : Wednesday, December 4, 2019 - 9:48:02 AM

Identifiers

Collections

UNIV-BREST | FNCLCC | IGR | UNIV-FCOMTE | BACLESSE | COMUE-NORMANDIE | IMMUNO | IBSAM | UNIV-PARIS-SACLAY

Citation

Alice Tison, Gilles Quéré, Laurent Misery, Elisa Funck-Brentano, François Danlos, et al.. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study. Arthritis & rheumatology, Wiley, 2019, ⟨10.1002/art.41068⟩. ⟨hal-02267195⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

80

Contact

Informations

CCSD